Daphne is an experienced investor and company builder, with over a decade of experience in real estate, biotech, and investment banking. She is the founder and CEO of NSG BioLabs, Singapore’s largest and leading biotech co-working laboratory and office space. She led the entire setup of NSG, including financing, operational setup, and recruited a team of internationally renowned professors, investors, and biotech executives to advise NSG and its companies.

She was one of the initial shareholders and co-founders of the Singapore- and US-based Engine Biosciences and previously served as a board director and head of finance and operations in its critical early days before and after venture financing. She continues to serve as an advisor to Engine Bio.

She currently also serves as Chief Investment Officer of D3 Capital and previously worked at Goldman Sachs and HSBC in the Investment Banking Division in Hong Kong and Singapore.

At D3, she has executed and overseen a number of multi-million investments in real estate and natural resources across Asia and USA. She also serves as a board director at selected portfolio companies. In 2013, she was a co-founder and investor in the 3.6M sq. ft. Golden City integrated real estate development in Yangon, Myanmar and helped drive the successful sale of the company at a valuation of US$110 million in 2016 achieving triple digit IRR for D3.

Daphne received her master’s from Stanford University’s School of Engineering and her bachelor’s from Purdue University (highest honors), and she is currently pursuing her master’s in biotechnology at Johns Hopkins University.

Trained as a biomedical engineer, Cheryl’s personal mission is to identify promising technologies that address unmet clinical needs and work directly with founders during the venture building process. She was a former Venture Partner at VentureHealth, a Silicon Valley-based healthcare fund, where she coordinated portfolio companies’ growth strategy in the Asia Pacific. Cheryl previously co-founded a mobile health company that facilitates the care of Alzheimer’s patients, which was successfully acquired in 2012 and led to her selection as one of Canada’s Next 36. She currently serves as a Board Member of Rootpath and HiFiBio Therapeutics.

Cheryl earned her joint PhD degree in Medical Engineering and Medical Physics from MIT and Harvard Medical School. Her research in building synthetic gene circuits and molecular systems have lead to publications in Science and Nature journals. Cheryl received her B.A.Sc. in Engineering Science and Biomedical Engineer from the University of Toronto.

Hingge brings over 25 years’ experience in venture capital, investment banking as well as corporate and business development.

He was most recently a Senior Advisor at WuXi Healthcare Ventures where he co-founded LifeMine Therapeutics. Prior to that, he was a Partner at Fidelity Biosciences (now F-Prime Capital) where he was involved with various venture stage investments in the biotechnology and medical technology sectors in the United States and Asia. Before joining Fidelity, Hingge was a Managing Director in the Private Equity Group at Lehman Brothers and was responsible for their principal investment activities in the private and public sectors of the healthcare industry. From 1998 to 2001 he held the position of Partner at Schroder Ventures Life Sciences and directed their US investment activities in the life sciences and therapeutics sectors.

Prior to Schroder Ventures, Hingge was at Robertson Stephens and at Lehman Brothers, both in the Healthcare Investment Banking Groups. He also worked at Chiron Corporation and Gensia, Inc in the areas of business development and strategic planning.

Hingge received an MD degree from Yale University School of Medicine and was trained in internal medicine at Brigham and Women’s Hospital and Harvard Medical School. Hingge also received an MBA degree from Harvard Business School.

Hingge has served on the Board of Directors of a number of privately-held biopharmaceutical and medical device companies. He currently serves on the Board of RootPath Genomics, Inc.

Tim is a world leader in the field of synthetic biology and has co-founded multiple successful venture-backed platform biotech companies, including Synlogic, Corvium, and Senti BioSciences, raising over $100MM in VC funding from Atlas, NEA, 8VC, the Gates Foundation, Orbimed, Deerfield, and Flybridge. At MIT, Timothy leads the Synthetic Biology Group and serves as an Associate Professor of Biological Engineering and Electrical Engineering and Computer Science. He is an Associate Member of the Broad Institute of MIT and Harvard. Timothy’s numerous accolades include the NIH New Innovator Award, the US Presidential Early Career Award for Scientists and Engineers, and the Ellison Medical Foundation New Scholar in Aging Award. He was also selected as a Siebel Scholar and Kavli Fellow by the National Academy of Sciences. Tim was nominated as the 2018 Xconomy Scientific Founder of the Year.

Tim received his S.B. and M.Eng. from MIT in Electrical Engineering and Computer Science, an M.D. from Harvard Medical School, and Ph.D. from the Harvard-MIT Health Sciences and Technology Medical Engineering and Medical Physics Program.

James has founded and led multiple initiatives aimed at increasing the pace of innovation in technology and healthcare. As Founding President of the MIT Biotechnology Group, James oversaw growth from four people to the largest biotechnology-focused organization at MIT. James also directs the MIT Alumni Life Sciences Angel Group, which connects MIT-affiliated startups with alumni investors. James is an active advisor for multiple startups and has spoken on machine learning, biotechnology, entrepreneurship, and innovation at top universities around the world—including in Mexico, Thailand, the Philippines, Brazil, Singapore, and Taiwan. Previously, James built quantitative models to trade financial derivatives in New York City.

​James pursued his doctoral studies in the MIT Media Lab, where he is currently a Research Affiliate, and received his S.M. from MIT’s Computer Science and Artificial Intelligence Laboratory as an NDSEG Fellow for his work designing machine learning algorithms to engineer next-generation biocatalysts. James also holds an Sc.B. with highest Latin and Departmental Honors in Computational Biology and Computer Science from Brown University.

Jeff brings extensive experience as a successful technology and healthcare businessperson and entrepreneur over the past decade. He has held CxO and senior executive roles at successful technology-driven start-ups and blue-chip companies. Jeff co-founded Engine Biosciences, and was previously with AAE (acquired by Expedia), AirAsia, Goodman Capital and Bain & Company. Two of the high-performing companies Jeffrey was instrumental in building reached sizable exits with a total valuation of $450MM. With his experience in venture, M&A, and company building, Jeff has made many active and promising investments in healthcare, biotechnology, and Internet companies from both the US and Asia.

Jeff graduated summa cum laude from the University of Pennsylvania.